companydata.dkcompanydata.dk

Nykode Therapeutics Denmark A/S: Financial statements 2022

CVR: 42038660

Source: annual report 2022, Danish Business Authority

01/01/2022 – 31/12/2022

Nykode Therapeutics Denmark A/S (CVR 42038660) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 38,639,042 and a net result of DKK 1,895,426 compared with DKK 578,082 the year before. That is an increase of 264.8% compared with the year before. Equity in the 2022 report amounted to DKK 2,873,508. The solvency ratio was 19.4%. The company had 23 employees in the financial year.

Gross Profit
DKK 38,639,042
Profit/Loss
DKK 1,895,426
Equity
DKK 2,873,508
Total Assets
DKK 14,830,214
Employees
23

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2022-38.6M1.9M2.9M23
2021-10.6M578K978K7

Official annual report

View the official annual report directly on the page with a Pro subscription.

Keep an eye on Nykode Therapeutics Denmark A/S

Get notified instantly about new financial statements, ownership changes, management changes and status changes.

Set up monitoring

Events in 2022

Louise Stubbe joins the board of Nykode Therapeutics Denmark A/SAug 15, 2022

As of August 15, 2022, Louise Stubbe has joined the board of directors of Nykode Therapeutics Denmark A/S.

Harald Gurvin joins the board of Nykode Therapeutics Denmark A/SAug 15, 2022

As of August 15, 2022, Harald Gurvin has joined the board of directors of Nykode Therapeutics Denmark A/S.

Katrine Hovgaard Husum leaves the board of Nykode Therapeutics Denmark A/SAug 15, 2022

As of August 15, 2022, Katrine Hovgaard Husum has left the board of directors of Nykode Therapeutics Denmark A/S.

Alf Gunnar Martin Nicklasson leaves the board of Nykode Therapeutics Denmark A/SAug 15, 2022

As of August 15, 2022, Alf Gunnar Martin Nicklasson has left the board of directors of Nykode Therapeutics Denmark A/S.

Nykode Therapeutics Denmark A/S: The 2021 annual report is outJul 8, 2022

Nykode Therapeutics Denmark A/S has published its annual report for 2021. Gross profit came to DKK 10,590,585, and the net result was DKK 578,082.

Alf Gunnar Martin Nicklasson joins the board of Nykode Therapeutics Denmark A/SJan 20, 2022

As of January 20, 2022, Alf Gunnar Martin Nicklasson has joined the board of directors of Nykode Therapeutics Denmark A/S.

Anders Tuv leaves the board of Nykode Therapeutics Denmark A/SJan 20, 2022

As of January 20, 2022, Anders Tuv has left the board of directors of Nykode Therapeutics Denmark A/S.

About Nykode Therapeutics Denmark A/S

Nykode Therapeutics Denmark A/S is a Danish company of the type Aktieselskab based in Kongens Lyngby, founded in 2021. The company is registered under the industry Virksomhedsrådgivning og anden ledelsesrådgivning. The company was previously named Vaccibody Denmark A/S. The management consists of Michael Thyrring Engsig. The board consists of Louise Stubbe (chair), Harald Gurvin and Michael Thyrring Engsig. The company is owned by Nykode Therapeutics ASA. The company has 11 employees (2026). In 2025, the company reported a gross profit of DKK 31,839,001 and a net result of DKK 1,347,127 compared with DKK 156,959 the year before. Equity in the 2025 report amounted to DKK 6,862,099.

Source: annual report 2025, Danish Business Authority

Other financial years